INFINITY PHARMACEUTICALS INC (INFI)       0.55  0 (0%)

0.55  0 (0%)

US45665G3039 - Common Stock - After market: 0.54 -0.01 (-1.82%)

INFINITY PHARMACEUTICALS INC0.55

NASDAQ:INFI (11/30/2022, 3:14:50 PM)0 (0%)

After market: 0.54 -0.01 (-1.82%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) 03-27 2023-03-27
Ins Owners 0.32% Inst Owners 34.64%
Market Cap 49.14M Shares 89.35M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 80
IPO 07-27 2000-07-27

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

INFI Daily chart

Company Profile

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase 1/1b clinical study.

Company Info

INFINITY PHARMACEUTICALS INC

1100 Massachusetts Avenue, Floor 4

Cambridge MASSACHUSETTS 02138

P: 16174531000.0

CEO: Adelene Q. Perkins

Employees: 33

Website: http://www.infi.com

INFI Twits

Here you can normally see the latest stock twits on INFI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example